Case Study: Two Instances of Idiopathic Plasmacytic Lymphadenopathy, a Subtype of Idiopathic Multicentric Castleman Disease, Accompanied by Xanthelasma Palpebrum from a Canadian Institution - Top-Institutions - MDSpire

Case Study: Two Instances of Idiopathic Plasmacytic Lymphadenopathy, a Subtype of Idiopathic Multicentric Castleman Disease, Accompanied by Xanthelasma Palpebrum from a Canadian Institution

  • By

  • Andrew A. Y. Chen

  • Vivian T. Yin

  • Paula Blanco

  • Mark Trinder

  • Richard I. Crawford

  • Ryan Henrie

  • Stephen Parkin

  • Nasreen Khalil

  • Mollie Carruthers

  • Lu Zhang

  • Luke Y. C. Chen

  • February 23, 2026

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    National Cancer Institute (NCI), NIH
    National Cancer Institute (NCI), NIH

    Bethesda, MD

    Key Differentiators

    • Hematology
    • Oncology
    • Immunology

  • #2

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Hematology
    • Oncology
    • Pathology

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Oncology
    • Immunology

  • #4

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Immunology

  • #5

    University of British Columbia
    University of British Columbia

    Vancouver, BC

    Key Differentiators

    • Hematology
    • Pathology

Original Source(s)

Case Study: Two Instances of Idiopathic Plasmacytic Lymphadenopathy, a Subtype of Idiopathic Multicentric Castleman Disease, Accompanied by Xanthelasma Palpebrum from a Canadian Institution

  • by Andrew A. Y. Chen, Vivian T. Yin, Paula Blanco, Mark Trinder, Richard I. Crawford, Ryan Henrie, Stephen Parkin, Nasreen Khalil, Mollie Carruthers, Lu Zhang, Luke Y. C. Chen

  • February 23, 2026

Related Content

Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study

Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS

Surgical Intervention for Emphysematous Osteomyelitis of the Spine in a Patient with Malnutrition and Anemia: A Unique Case Study